Centre for Advanced Medical Products
| Reference number | |
| Coordinator | Umeå universitet - Institutionen för integrativ medicinsk biologi |
| Funding from Vinnova | SEK 52 000 000 |
| Project duration | January 2018 - December 2024 |
| Status | Ongoing |
| Venture | Center for biologics |
| Call | Center Biologics 2017 |
Important results from the project
CAMP established a national network of over 40 actors from academia, healthcare and industry, and implemented several R&D projects in advanced therapies (ATMP). The results include product and process development, support for clinical trials, and the development of pre-GMP and GMP infrastructure that has been widely used. The project has strengthened Sweden´s innovation system and laid the foundation for long-term growth, knowledge transfer and improved access to treatments for patients.
Expected long term effects
CAMP´s results are expected to have long-term effects on Sweden´s capacity to develop and introduce advanced therapies. CAMP has laid the foundation for a national infrastructure and collaboration that promotes clinical application and commercialization. This will be taken forward by sustainable initiatives such as CCRM Nordic, the hospital ATMP centres and the association ATMP Sweden. In the long term, this can strengthen Sweden´s global position and improve patients´ access to new treatments.
Approach and implementation
During 2018–2024, CAMP ran several R&D projects with actors from academia, industry and healthcare. A balanced portfolio focussed on product technology, process development, infrastructure and translation. Early engagement challenges were resolved through strategic changes that improved co-financing. Thereafter, the collaboration worked well, and internal communication routines allowed for efficient follow-up. Partnership with ATMP2030 was a strength and contributed to a robust innovationsystem.